Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Illumina

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Jan 20, 2021

Illumina Wins UK Patent Infringement Suit Against BGI, Affiliates

Illumina said it plans to pursue a permanent injunction against BGI in the UK until the four patents expire — three in 2023 and one in 2027.

Jan 20, 2021

Boosting Viral Surveillance

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

Jan 11, 2021

Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

Jan 11, 2021

Multi-Cancer Molecular Screening Assays Primed for Clinical Implementation in 2021

Premium

Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.

Jan 11, 2021

BGI Sues Illumina for Antitrust Violation, Claims Firm Obtained Sequencing Patents Through Fraud

In their complaint the plaintiffs claimed Illumina fraudulently obtained two US patents by concealing a reference from the patent office.

Jan 11, 2021

After Year of Scaling Up, Africa's 54gene Seeks Research Projects, Pharma Partnerships

Premium

The African health technology company 54gene is eager for partnerships with researchers and biopharmaceutical companies alike.

Jan 11, 2021

Grail Inks Deals With Amgen, AstraZeneca, Bristol Myers Squibb for MRD Test Development

The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.

Jan 11, 2021

Helix Obtains FDA Authorization for Exome Sequencing Platform, Alzheimer's Disease Risk Test

The Helix Laboratory Platform is the first whole-exome sequencing platform to receive do novo authorization by the agency and paves the way for others.

Jan 05, 2021

Illumina, Helix Collaborate on CDC-Coordinated Coronavirus Surveillance

The partners have already identified cases in the US of the novel, highly transmissible SARS-CoV-2 variant that was first reported in the UK.

Jan 05, 2021

New York Study Aims to Assess Utility of Clinical Whole-Genome Sequencing Across Diseases

Premium

Over the next year or so, the investigators plan to sequence the genomes of 3,000 patients with cancer, heart disease, diabetes, or neurological disorders.

Pages

The Scan

Open Spot

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

US to Remain in WHO

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

Dip Possible

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

Nature Papers Examine Australian Lungfish Genome, Essential E. Coli Genes

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.

What's Popular?

In Illumina

  1. Illumina Wins UK Patent Infringement Suit Against BGI, Affiliates

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.